Erythropoietin

Generic Name: Erythropoietin

Brand Names: Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit

Drug Type: Biotech

Chemical Formula: -

CAS Number: 11096-26-7

Unique Ingredient Identifier: 64FS3BFH5W

Background: Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...

Indication: 用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。

Associated Conditions: Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine

Associated Therapies: -

Clinical Trials

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

Phase 2

Withdrawn

Conditions: Cancer

Interventions: Drug: Placebo
Drug: Procrit

First Posted Date: 2008-02-27

Last Posted Date: 2021-08-06

Lead Sponsor: University of Louisville

Registration Number: NCT00624312

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States

Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients

Phase 2

Conditions: Multiple Trauma

Interventions: Drug: placebo
Drug: erythropoietin

First Posted Date: 2008-02-25

Last Posted Date: 2010-11-18

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT00622934

Locations: 🇮🇷
Sina Hospital, Tehran, Iran, Islamic Republic of

The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group

Phase 1

Conditions: Transplantation, Kidney

Interventions: Drug: Placebo
Drug: Erythropoietin

First Posted Date: 2008-02-18

Last Posted Date: 2008-03-28

Lead Sponsor: Labbafinejhad Hospital

Target Recruit Count: 50

Registration Number: NCT00617474

Erythropoietin Treatment in Extremely Low Birth Weight Infants

Not Applicable

Completed

Conditions: Infant, Low Birth Weight
Anemia

Interventions: Drug: epoetin beta

First Posted Date: 2008-01-15

Last Posted Date: 2008-01-15

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 219

Registration Number: NCT00593801

Locations: 🇩🇪
Dept of Neonatolgy Charité University Medicine Berlin, Berlin, Germany

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

Phase 2

Terminated

Conditions: Infant, Premature
Erythropoietin
Brain Injury
Intraventricular Hemorrhage
Periventricular Leukomalacia
Neurodevelopmental Outcomes
Randomized Clinical Trial

Interventions: Drug: Saline placebo
Drug: Erythropoietin

First Posted Date: 2008-01-10

Last Posted Date: 2013-07-30

Lead Sponsor: Atlantic Health System

Target Recruit Count: 22

Registration Number: NCT00589953

Locations: 🇺🇸
Morristown Medical Center, Morristown, New Jersey, United States

A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients

Not Applicable

Completed

Conditions: Chronic Disease
Kidney Diseases
Cardiovascular Diseases

First Posted Date: 2007-11-26

Last Posted Date: 2011-06-16

Lead Sponsor: Hospital Authority, Hong Kong

Target Recruit Count: 66

Registration Number: NCT00563355

Locations: 🇨🇳
Prince of Wales Hospital, Hong Kong, China

Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP)

Phase 3

Terminated

Conditions: Spinal Cord Injury

Interventions: Drug: Erythropoietin
Drug: Methylprednisolone

First Posted Date: 2007-11-20

Last Posted Date: 2019-03-14

Lead Sponsor: Niguarda Hospital

Target Recruit Count: 10

Registration Number: NCT00561067

Locations: 🇮🇹
A.O. Ospedale Ca' Granda, Milan, Italy

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Phase 4

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: SoC therapy
Drug: irbesartan
Drug: ramipril
Drug: hydrochlorothiazide
Drug: furosemide
Drug: amlodipine
Drug: atenolol
Drug: doxazosin
Drug: clonidine
Drug: insulin
Drug: simvastatin
Drug: fibrate
Drug: erythropoietin
Drug: aspirin

First Posted Date: 2007-09-27

Last Posted Date: 2020-08-03

Lead Sponsor: University of Campania "Luigi Vanvitelli"

Target Recruit Count: 850

Registration Number: NCT00535925

Locations: 🇮🇹
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy

NESP Pediatric Study

Phase 3

Completed

Conditions: Pre-dialysis
End Stage Renal Disease

Interventions: Drug: rHuEPO
Drug: darbepoetin alfa

First Posted Date: 2007-09-10

Last Posted Date: 2013-05-08

Lead Sponsor: Amgen

Target Recruit Count: 120

Registration Number: NCT00527137

Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients

Phase 4

Conditions: Chronic Hepatitis C

Interventions: Drug: ribavirin
Drug: Peginterferon alfa-2a
Drug: epoetin beta

First Posted Date: 2007-09-10

Last Posted Date: 2009-01-29

Lead Sponsor: Hospital Carlos III, Madrid

Target Recruit Count: 384

Registration Number: NCT00526448

Locations: 🇪🇸
Hospital Parc Taulí, Sabadell, Barcelona, Spain
🇪🇸
Hospital do Meixoeiro, Vigo, Pontevedra, Spain
🇪🇸
Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain

and more 37 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy